Skip to content

Best Peptides for Gut Health, Ranked by Human Evidence

Gut peptides ranked by human trials: approved drugs for constipation and short bowel lead. BPC-157's one gut trial showed no significant benefit; KPV has none.

Sebastian Hunter, Founder and EditorWritten bySebastian Hunter, Founder and EditorI'm a 42-year-old senior advisor and distance runner who came to peptides as a sceptic. I'm not a doctor: I read the research, run my own experiment and keep honest notes. Read full bio

The short version

The peptides with real gut trials are prescription drugs for specific diagnoses: linaclotide and plecanatide for chronic constipation, and teduglutide for short bowel syndrome. Larazotide eased coeliac symptoms at one dose before its Phase 3 trial was stopped. Of the research peptides sold for gut health, BPC-157 has the most human data, and its one placebo-controlled trial found no significant difference from placebo. KPV has only mouse data.

  • Linaclotide, plecanatide and teduglutide have large placebo-controlled trials and FDA approval for specific gut conditions.
  • BPC-157's gut evidence is one 53-person colitis trial, known only from a meeting abstract, with no significant difference.
  • KPV reduced colitis in mice. FDA found no study of it in people.
  • Zinc carnosine and collagen peptides, sold as supplements, have only small or uncontrolled human studies.

The peptides with the strongest human evidence for the gut are prescription drugs for specific diagnoses: linaclotide and plecanatide for chronic constipation, and teduglutide for short bowel syndrome. Of the research peptides sold for gut health, BPC-157 has the most human data, and its one placebo-controlled trial found no significant benefit.

The ranking below orders compounds by how much human gut data they have and how good it is. A higher rank means better evidence, not that a compound will fix your gut. The top three were tested only in people with a diagnosed condition. Related goals: recovery and healing and immune support.

Peptides for gut health compared

RankCompoundHuman evidence on the gutWhat was measuredUS legal statusOur page
1Linaclotide, plecanatidePhase 3 trials: 1,276 patients (linaclotide, 2 trials), 1,394 (plecanatide)Complete bowel movements per week in chronic constipationPrescription drugs (FDA-approved)FDA-approved peptides
2TeduglutidePhase 3 trial, 86 patientsNeed for intravenous nutrition in short bowel syndromePrescription drug (FDA-approved)FDA-approved peptides
3LarazotidePhase 2b trial, 342 patients; Phase 3 stoppedCoeliac symptoms on a gluten-free dietNot approvedNone yet
4Zinc carnosine1 crossover trial, 10 healthy volunteersGut permeability during a painkiller courseDietary supplementNone yet
5BPC-1571 placebo-controlled trial, 53 patients (abstract only); healthy-volunteer safety studiesUlcerative colitis activity scoreResearch chemicalBPC-157
6Collagen peptides1 uncontrolled pilot, 14 completersSelf-reported digestive symptomsDietary supplementCollagen peptides
7KPVNone; mouse colitis studiesGut inflammation in miceResearch chemicalKPV
8TB-500, LL-37, GHK-CuNone foundNothing on the gutResearch chemicals (GHK-Cu: cosmetic)TB-500

1. Linaclotide and plecanatide: approved for chronic constipation

Linaclotide is a 14-amino-acid peptide taken by mouth. It acts in the gut and is barely absorbed. Two 12-week trials enrolled 1,276 people with chronic constipation. On linaclotide, 16% to 21% reached the main goal for weekly complete bowel movements, against 3% to 6% on placebo, and diarrhoea led 4.2% to stop Lembo 2011 - Lembo AJ, Schneier HA, Shiff SJ et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med. 2011;365(6):527-36., in the references below.

Plecanatide is a 16-amino-acid analogue of uroguanylin, a natural gut hormone. In a 12-week trial of 1,394 people with chronic constipation, about 20% on plecanatide were sustained responders, against 10% on placebo Miner 2017 - Miner PB Jr, Koltun WD, Wiener GJ et al. A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation. Am J Gastroenterol. 2017;112(4):613-621., in the references below.

Both are FDA-approved for chronic idiopathic constipation and constipation-predominant irritable bowel syndrome (IBS-C). Linzess, the linaclotide brand, is also approved for children with some forms of constipation. Both labels carry a boxed warning against use in young children, because the drugs caused fatal dehydration in young mice.

2. Teduglutide: approved for short bowel syndrome

Teduglutide is a 33-amino-acid analogue of GLP-2, a gut hormone that helps the intestinal lining grow. A 24-week trial enrolled 86 people with short bowel syndrome who depended on intravenous nutrition. On teduglutide, 63% cut that need by more than 20%, against 30% on placebo Jeppesen 2012 - Jeppesen PB, Pertkiewicz M, Messing B et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology. 2012;143(6):1473-1481.e3., in the references below.

Sold as Gattex, it is FDA-approved for short bowel syndrome in adults and children aged 1 and older who depend on intravenous (parenteral) support. Its label warns that it can speed the growth of existing tumours.

3. Larazotide: promising in coeliac disease, then stopped

Larazotide is a peptide designed to act on the tight junctions that seal the gaps between gut-lining cells. A 12-week trial enrolled 342 adults with coeliac disease who still had symptoms on a gluten-free diet. The lowest dose (0.5 mg) reduced symptoms more than placebo. The two higher doses did no better than placebo Leffler 2015 - Leffler DA, Kelly CP, Green PH et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology. 2015;148(7):1311-9.e6., in the references below.

In June 2022 the developer, 9 Meters Biopharma, stopped its Phase 3 trial. An independent statistician had found that too many new patients would be needed for a meaningful result. I found no later coeliac trial and no approval anywhere.

4. Zinc carnosine: one small trial on gut permeability

Zinc carnosine pairs zinc with carnosine, a two-amino-acid peptide. In a crossover trial, 10 healthy volunteers took the painkiller indomethacin for 5 days, with zinc carnosine or placebo. On placebo, gut permeability roughly tripled; with zinc carnosine, it did not rise significantly Mahmood 2007 - Mahmood A, FitzGerald AJ, Marchbank T et al. Zinc carnosine, a health food supplement that stabilises small bowel integrity and stimulates gut repair processes. Gut. 2007;56(2):168-75., in the references below.

It was a 5-day test in 10 healthy people. Zinc carnosine is sold in the US as a dietary supplement, which FDA does not approve before sale.

5. BPC-157: the research peptide with the most human data

BPC-157’s gut reputation rests mainly on rat studies. In people, its one placebo-controlled gut trial gave 53 people with mild to moderate ulcerative colitis a BPC-157 or placebo enema once a day for two weeks. The colitis activity score fell 3.2 points on BPC-157 and 1.6 on placebo, and the difference between groups was not statistically significant. FDA found the trial only as a meeting abstract.

FDA’s July 2026 review of that trial concluded the data do not support BPC-157 for ulcerative colitis. The other gut studies FDA listed gave BPC-157 enemas to healthy volunteers, where headache and flatulence were the most common side effects. FDA found no study of oral or injected BPC-157 in ulcerative colitis.

Some users credit it anyway. The fitness author Ben Greenfield wrote in 2016 that injected BPC-157 calmed his gut inflammation (Ben Greenfield Life). That is one person’s account, not a controlled result. BPC-157 is a research chemical, not approved for human use. More: BPC-157 and oral vs injectable BPC-157.

6. Collagen peptides: an uncontrolled pilot

In an 8-week app-based study, women took 20 g of collagen peptides a day. Of 40 recruited, 14 finished, and 13 of those reported fewer digestive symptoms, including bloating Abrahams 2022 - Abrahams M, O'Grady R, Prawitt J. Effect of a Daily Collagen Peptide Supplement on Digestive Symptoms in Healthy Women: 2-Phase Mixed Methods Study. JMIR Form Res. 2022;6(5):e36339., in the references below. There was no placebo group, most participants dropped out, and the study was funded by Rousselot, which makes the collagen it tested. Collagen peptides are sold as dietary supplements. More: collagen peptides.

7. KPV: mouse colitis only

KPV, a three-amino-acid fragment of the hormone alpha-MSH, reduced gut inflammation in mouse models of colitis Dalmasso 2008 - Dalmasso G, Charrier-Hisamuddin L, Nguyen HT et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-78., in the references below Kannengiesser 2008 - Kannengiesser K, Maaser C, Heidemann J et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-31., in the references below. FDA’s July 2026 review found no clinical study of KPV in people. It is a research chemical. More: KPV and the BPC-157 and KPV stack.

8. TB-500, LL-37 and GHK-Cu: no human gut studies

A PubMed search on 3 October 2026 found no clinical trial of TB-500 or thymosin beta-4 for any gut condition. I found none giving LL-37 or GHK-Cu for one. More: TB-500, LL-37 and GHK-Cu.

Choosing a seller

This page does not rank sellers. The approved drugs come only on prescription, from a pharmacy. For research peptides, the vendor checklist and how to read a COA cover what a seller can and can’t show you.

Common questions

Does BPC-157 heal gut issues?

That has not been shown in people. Its one placebo-controlled gut trial gave 53 people with ulcerative colitis a BPC-157 or placebo enema for two weeks. Disease activity scores fell more on BPC-157, but the difference was not statistically significant, and FDA found the trial only as a meeting abstract. FDA concluded the data do not support BPC-157 for ulcerative colitis. Its gut reputation rests mainly on rat studies.

Can peptides improve gut health?

Some peptide drugs treat specific gut conditions, with large trials behind them: linaclotide and plecanatide for chronic constipation, and teduglutide for short bowel syndrome. All three are prescription medicines for diagnosed conditions. For general gut health in healthy people, I found no peptide with a controlled trial showing a benefit.

What is the best peptide for gut healing?

It depends on the diagnosis, and none is a general gut healer. Teduglutide is approved to help people with short bowel syndrome need less intravenous nutrition. Among research peptides, BPC-157 has the most human data, and its one patient trial was not significant. KPV, TB-500 and LL-37 have no human gut studies I could find. Persistent gut symptoms are worth a diagnosis before any of these.

Does oral BPC-157 work for the gut?

I found no human evidence on that. The BPC-157 gut studies FDA reviewed all used enemas, and FDA found no study of oral BPC-157 in ulcerative colitis. One oral BPC-157 safety trial in healthy volunteers was registered in Mexico, but FDA found no posted results or published paper.

Is there human evidence for KPV in the gut?

I found none. KPV reduced gut inflammation in mouse models of colitis. But FDA's July 2026 review found no clinical study of KPV in people, and the nomination it reviewed cited none. It is sold as a research chemical, not an approved medicine.

What is the downside of taking peptides for gut health?

For the approved drugs, the downsides are on the label. Linaclotide and plecanatide can cause diarrhoea and must not be given to young children. Teduglutide carries a warning that it can speed the growth of existing tumours. For research peptides such as BPC-157 and KPV, there is no long-term human safety data, and no regulator checks that a vial matches its label.

References (18 sources)

Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.

  1. 1.Lembo AJ, Schneier HA, Shiff SJ et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med. 2011;365(6):527-36.Randomised trialPMID 21830967
  2. 2.Miner PB Jr, Koltun WD, Wiener GJ et al. A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation. Am J Gastroenterol. 2017;112(4):613-621.Randomised trialPMID 28169285full text
  3. 3.Jeppesen PB, Pertkiewicz M, Messing B et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology. 2012;143(6):1473-1481.e3.Randomised trialPMID 22982184
  4. 4.Leffler DA, Kelly CP, Green PH et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology. 2015;148(7):1311-9.e6.Randomised trialPMID 25683116full text
  5. 5.Mahmood A, FitzGerald AJ, Marchbank T et al. Zinc carnosine, a health food supplement that stabilises small bowel integrity and stimulates gut repair processes. Gut. 2007;56(2):168-75.Randomised trialPMID 16777920full text
  6. 6.Abrahams M, O'Grady R, Prawitt J. Effect of a Daily Collagen Peptide Supplement on Digestive Symptoms in Healthy Women: 2-Phase Mixed Methods Study. JMIR Form Res. 2022;6(5):e36339.StudyPMID 35639457full text
  7. 7.Dalmasso G, Charrier-Hisamuddin L, Nguyen HT et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-78.StudyPMID 18061177full text
  8. 8.Kannengiesser K, Maaser C, Heidemann J et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-31.StudyPMID 18092346
  9. 9.LINZESS (linaclotide) label - indications (IBS-C in adults and children 7 and older, chronic idiopathic constipation in adults, functional constipation in children 2 and older), boxed warning on use under age 2, and "a 14-amino acid peptide".- DailyMed, US National Library of Medicinelabel
  10. 10.TRULANCE (plecanatide) label - indications (chronic idiopathic constipation and IBS-C in adults), boxed warning on use under age 6, and a 16-amino-acid analogue of uroguanylin.- DailyMed, US National Library of Medicinelabel
  11. 11.GATTEX (teduglutide) label - indication (short bowel syndrome in adults and children 1 year and older who depend on parenteral support), a 33-amino-acid GLP-2 analogue, and warnings including acceleration of neoplastic growth.- DailyMed, US National Library of Medicinelabel
  12. 12.Celiac Disease Foundation, 21 June 2022 - 9 Meters discontinues Phase 3 clinical trial for potential celiac disease drug larazotide, after an independent statistician found too many new patients would be needed for scientifically meaningful results.- Celiac Disease Foundationnews
  13. 13.NIH Dietary Supplement Label Database, label 188864 (API record) - Swanson Zinc Carnosine capsules (PepZinGI zinc-carnosine), directions "As a dietary supplement", with a structure/function claim.- NIH Office of Dietary Supplementsdatabase
  14. 14.FDA briefing document for the Pharmacy Compounding Advisory Committee meeting, 23-24 July 2026 - evaluation of BPC-157. Summarises the 53-person ulcerative colitis enema trial (meeting abstract only), the healthy-volunteer enema studies, and the registered oral trial with no results.- US Food and Drug Administrationregulatory
  15. 15.FDA briefing document for the Pharmacy Compounding Advisory Committee meeting, 23-24 July 2026 - evaluation of KPV. FDA did not identify clinical studies of KPV in humans, and none of the nomination's references studied it in people.- US Food and Drug Administrationregulatory
  16. 16.FDA - Questions and Answers on Dietary Supplements. FDA does not approve dietary supplements before they are marketed.- US Food and Drug Administrationregulatory
  17. 17.NCBI E-utilities esearch - thymosin beta-4 or TB-500 with colitis, bowel, intestinal, gut or gastric terms, limited to clinical trials, queried 3 October 2026: zero records.- US National Library of Medicinedatabase
  18. 18.Ben Greenfield Life, 16 May 2016 - BPC 157: How To Use It. Greenfield writes that he injected BPC-157 himself and credits it with calming gut inflammation, among other effects.- Ben Greenfield Lifeother

Keep reading

Related guides